Quanta Biosciences said this week that Integrated DNA Technologies will manufacture assays that Quanta has developed for quantifying microRNAs.
Under the terms of the deal, IDT will produce the assays, which will allow scientists to detect and profile mature miRNA sequences; and will market them through an online catalog directly to customers of Quanta.
Quanta said that early-access customers, who have not been disclosed, have used the assays for toxicology screening during drug development; and quality control of stem cell pluripotency and differentiation.
Financial terms of the deal were not disclosed.
Based in Gaithersburg, Md., Quanta develops reagents for PCR, qPCR, and cDNA applications.